Citadel Advisors’s Galera Therapeutics, Inc. Common Stock GRTX Stock Holding History

Citadel Advisors’s Portfolio GRTX Stock Details GRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-10,200	Closed	-$1.79K	–	15512
2023 Q3	$1.79K	Sell	10,200 -12,500	-55%	-$15.5K	﹤0.01%	13806
2023 Q2	$70.8K	Buy	22,700 +21,200	+1,413%	+$63.1K	﹤0.01%	11378
2023 Q1	$3.84K	Buy	1,500 +600	+67%	+$1.24K	﹤0.01%	14003
2022 Q4	$1.34K	Buy	+900	New	+$1.46K	﹤0.01%	14487
2022 Q2	–	Sell	-59,900	Closed	-$143K	–	14426
2022 Q1	$143K	Buy	59,900 +39,200	+189%	+$102K	﹤0.01%	11915
2021 Q4	$95K	Buy	+20,700	New	+$68.4K	﹤0.01%	12771

Other funds holding GRTX

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Citadel Advisors's GRTX Position: Q1 2024 in Review

Citadel Advisors sold out of Galera Therapeutics, Inc. Common Stock (GRTX) in Q1 2024, closing a stake of 590,052 shares — an estimated $116K sold.

Citadel Advisors first reported a position in GRTX in Q1 2022 and held it in 6 quarters. The position peaked at $330K in Q1 2022. 36 funds tracked by Wall St. Rank hold GRTX as of Q1 2024.

Citadel Advisors reported no remaining Galera Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Citadel Advisors sold 590,052 Galera Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $116K.
Citadel Advisors first reported a position in Galera Therapeutics, Inc. Common Stock in Q1 2022 and held it in 6 quarters.
Citadel Advisors's Galera Therapeutics, Inc. Common Stock position peaked at $330K in Q1 2022.
36 funds tracked by Wall St. Rank held Galera Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Citadel Advisors's 13F filing for Q1 2024, filed 15 May 2024.